Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CL-82198, a selective MMP-13 inhibitor, serves as a pharmacological intervention to halt the progression of osteoarthritis (OA). Its mechanism of action involves binding to the S1’ pocket of MMP-13, ensuring its selectivity and preventing inhibition of other MMPs.
説明 | CL-82198, a selective MMP-13 inhibitor, serves as a pharmacological intervention to halt the progression of osteoarthritis (OA). Its mechanism of action involves binding to the S1’ pocket of MMP-13, ensuring its selectivity and preventing inhibition of other MMPs. |
In vitro | CL-82198 decreases CTGF and TGF-β1 protein levels in hepatic stellate cells[3]. CL-82198 (10 μM; 24 hours) obviously reduces LS174 cell migration[1]. |
In vivo | CL82198 (1-10 mg/kg; i.p.; every other day for 12 weeks) treatment avoids and decelerates MLI-induced osteoarthritis progression. |
分子量 | 302.37 |
分子式 | C17H22N2O3 |
CAS No. | 307002-71-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (330.72 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CL-82198 307002-71-7 Proteases/Proteasome MMP Inhibitor CL82198 inhibit Matrix metalloproteinases CL 82198 inhibitor